GH RESEARCH PLC DL-025 (1KA) - Total Liabilities
Based on the latest financial reports, GH RESEARCH PLC DL-025 (1KA) has total liabilities worth €12.86 Million EUR (≈ $15.03 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of GH RESEARCH PLC DL-025 to measure how many days the company can operate on defensive assets alone.
GH RESEARCH PLC DL-025 - Total Liabilities Trend (2021–2025)
This chart illustrates how GH RESEARCH PLC DL-025's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are GH RESEARCH PLC DL-025's assets to evaluate the company's liquid asset resilience ratio.
GH RESEARCH PLC DL-025 Competitors by Total Liabilities
The table below lists competitors of GH RESEARCH PLC DL-025 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Televisa S.A.B
MX:TLEVISACPO
|
Mexico | MX$122.08 Billion |
|
Jiangsu Evergreen New Material Technology Inc. Co. A
SHG:603125
|
China | CN¥171.81 Million |
|
Arcelik AS
IS:ARCLK
|
Turkey | TL513.70 Billion |
|
VIA Technologies Inc
TW:2388
|
Taiwan | NT$15.11 Billion |
|
PROG Holdings Inc
NYSE:PRG
|
USA | $1.27 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥379.82 Million |
|
Afry AB
ST:AFRY
|
Sweden | Skr15.56 Billion |
|
Canfor Corporation
TO:CFP
|
Canada | CA$2.43 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down GH RESEARCH PLC DL-025's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of GH RESEARCH PLC DL-025.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GH RESEARCH PLC DL-025's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GH RESEARCH PLC DL-025 (2021–2025)
The table below shows the annual total liabilities of GH RESEARCH PLC DL-025 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €8.53 Million ≈ $9.97 Million |
-8.53% |
| 2024-12-31 | €9.32 Million ≈ $10.90 Million |
+27.14% |
| 2023-12-31 | €7.33 Million ≈ $8.57 Million |
+61.28% |
| 2022-12-31 | €4.55 Million ≈ $5.31 Million |
+65.37% |
| 2021-12-31 | €2.75 Million ≈ $3.21 Million |
-- |
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more